Sara Bay Financial lowered its stake in Abbott Laboratories (NYSE:ABT – Get Rating) by 6.4% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,237 shares of the healthcare product maker’s stock after selling 564 shares during the quarter. Abbott Laboratories comprises 0.4% of Sara Bay Financial’s portfolio, making the stock its 27th biggest holding. Sara Bay Financial’s holdings in Abbott Laboratories were worth $975,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also modified their holdings of the company. Capital Investment Advisors LLC raised its stake in Abbott Laboratories by 4.2% during the 4th quarter. Capital Investment Advisors LLC now owns 13,335 shares of the healthcare product maker’s stock valued at $1,877,000 after purchasing an additional 534 shares during the period. Minot Wealth Management LLC raised its stake in Abbott Laboratories by 3.8% during the 4th quarter. Minot Wealth Management LLC now owns 58,450 shares of the healthcare product maker’s stock valued at $8,226,000 after purchasing an additional 2,147 shares during the period. Gradient Investments LLC raised its stake in Abbott Laboratories by 6.2% during the 4th quarter. Gradient Investments LLC now owns 71,707 shares of the healthcare product maker’s stock valued at $10,092,000 after purchasing an additional 4,160 shares during the period. TRH Financial LLC raised its stake in Abbott Laboratories by 23.2% during the 1st quarter. TRH Financial LLC now owns 73,590 shares of the healthcare product maker’s stock valued at $8,710,000 after purchasing an additional 13,864 shares during the period. Finally, Samalin Investment Counsel LLC grew its holdings in Abbott Laboratories by 5.5% during the 4th quarter. Samalin Investment Counsel LLC now owns 3,311 shares of the healthcare product maker’s stock valued at $466,000 after buying an additional 172 shares in the last quarter. 73.46% of the stock is currently owned by institutional investors.
Several equities analysts have weighed in on ABT shares. Royal Bank of Canada cut their price target on Abbott Laboratories from $146.00 to $143.00 and set an “outperform” rating for the company in a report on Thursday, April 21st. Wells Fargo & Company cut their price target on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating for the company in a report on Friday, April 8th. Bank of America started coverage on Abbott Laboratories in a report on Tuesday, March 1st. They set a “buy” rating and a $140.00 price target for the company. Citigroup cut their price target on Abbott Laboratories from $154.00 to $125.00 and set a “na” rating for the company in a report on Tuesday, May 17th. Finally, Raymond James dropped their target price on Abbott Laboratories from $143.00 to $135.00 and set an “outperform” rating for the company in a report on Thursday, April 21st. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $140.25.
Shares of NYSE ABT opened at $103.95 on Wednesday. Abbott Laboratories has a 12-month low of $101.24 and a 12-month high of $142.60. The company has a current ratio of 1.85, a quick ratio of 1.40 and a debt-to-equity ratio of 0.48. The stock has a market cap of $182.01 billion, a P/E ratio of 24.12, a PEG ratio of 3.70 and a beta of 0.73. The business’s fifty day simple moving average is $113.22 and its 200-day simple moving average is $121.75.
Abbott Laboratories (NYSE:ABT – Get Rating) last issued its quarterly earnings data on Wednesday, April 20th. The healthcare product maker reported $1.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.47 by $0.26. Abbott Laboratories had a return on equity of 28.72% and a net margin of 17.35%. The firm had revenue of $11.90 billion during the quarter, compared to the consensus estimate of $11 billion. During the same period in the previous year, the firm posted $1.32 EPS. The company’s quarterly revenue was up 13.8% compared to the same quarter last year. On average, equities analysts forecast that Abbott Laboratories will post 4.84 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Stockholders of record on Friday, July 15th will be given a dividend of $0.47 per share. The ex-dividend date is Thursday, July 14th. This represents a $1.88 annualized dividend and a dividend yield of 1.81%. Abbott Laboratories’s payout ratio is 43.62%.
Abbott Laboratories Profile (Get Rating)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
- The Rebound In Winnabego Is On
- Global Events Could Be A Boon For Potash Stocks
- SeaWorld Entertainment Stock Can be Caught on the Downdraft
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.